Maitake (scientific name Grifola frondosa) is indigenous to the northeastern part of Japan. In Japan, Maitake can grow to more than 20 kilograms in size, earning this giant mushroom the title King of Mushrooms. Maitake is so named, not only for its large size but also for its amazing health benefits. Apart from it's health benefits, it is also highly sought after for it's excellent taste.
Medicinal mushroom derived β-glucans are notable for their ability to modulate the immune system. Sources of beta-glucan include various species of mushrooms, such as reishi, shiitake, and maitake. β-Glucans are known as "biological response modifiers" because of their ability to activate the immune system. Immunologists have discovered that receptors on the surface of innate immune cells called dectin-1 and complement receptor 3 (CR3 or CD11b/CD18) are responsible for binding to β-glucans, allowing the immune cells to recognize them.
Maitake beta-glucan MD-Fraction is the original patented product which is made in Japan to ISO standards.
A phase I/II human trial, conducted by Memorial Sloan–Kettering Cancer Center, showed Maitake could stimulate the immune system of breast cancer patients. Small experiments with human cancer patients, have shown Maitake can stimulate immune system cells like NK cells. In vitro research has also shown that Maitake can stimulate immune system cells, confirming the clinical experiments in humans.
Small studies with human cancer patients revealed that the Maitake D-fraction portion of the Maitake mushroom possess anti-cancer activity. In vitro research demonstrated that Maitake has potential anti-metastatic properties. In 1997, the US Food and Drug Administration (FDA) approved an Investigational New Drug Application for a portion of the mushroom.
Research has shown Maitake has a hypoglycemic effect, and may be beneficial for the management of diabetes. The reason Maitake lowers blood sugar is due to the fact the mushroom contains a natural alpha glucosidase inhibitor. Alpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates. Since cancer cells have a preference for glucose, lowering blood sugar levels in cancer patients tends to produce beneficial effects for the patient. Clinical studies in cancer patients with Metformin, a common anti-diabetic drug, show similar beneficial effects.
Maitake contains antioxidants and may partially inhibit the enzyme cyclooxygenase. An experiment showed that an extract of Maitake inhibited angiogenesis via inhibition of the vascular endothelial growth factor (VEGF).
Maitake beta-glucan MD-Fraction therapy:
Purchase your Colostrum MAF here using PayPal or credit card.Heart Pharmacy website
Thank you very much for your participation at the Saisei Mirai 2016 Integrative Medical Therapies conference in Osaka, held on Sunday 13th November 2016.2016 Integrative Medical Therapies conference - Osaka, Japan
Dr Toshio Inui
Dr. Toshio Inui gave a presentation of the electric field therapy and second-generation GcMAF and colostrum MAF at a conference which was held in Jakarta, Indonesia on July 22, 2016.
14 to 15-JUL-2016
Dr. Shinichiro Akiyama at International Pharmacy Conference, which was held in the United States Philadelphia, Pennsylvania on July 14 to 15, 2016, the Clinical experience of colostrum derived protein against solid cancer has been announced as the Keynote Speaker.
New research papers on Oral Colostrum GcMAF for Chronic Fatigue Syndrome (CFS) and serious infection published in Anticancer Research journal.Research paper
Clinical application of Second Generation GcMAF and oral GcMAF
Dr Toshio Inui
Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections (PDF)
Dr Toshio Inui
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy (PDF), PPT
Dr Toshio Inui
New research papers on GcMAF and integrative cancer immunotherapy treatment written in collaboration with the University of Tokushima, Kanazawa University and Kobe University Graduate School of Medicine researchers and Saisei Mirai published in Anticancer Research journal.Research paper
The results show that 2nd Generation GcMAF is stable for 1 year at 4 °C, for 14 days at room temperature (around 20 °C), and for 7 days at 40 °C.
See Research and references for more details on experiments on macrophage phagocytic activity and stability of our GcMAF.
Deng G, Lin H, Seidman A, et al. (2009). "A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects". Journal of Cancer Research and Clinical Oncology. 135 (9): 1215–21.
Kodama N, Komuta K, Nanba H (2003). "Effect of Maitake (Grifola frondosa) D-Fraction on the activation of NK cells in cancer patients". Journal of Medicinal Food. 6 (4): 371–7.
Kodama N, Komuta K, Sakai N, Nanba H (2002). "Effects of D-Fraction, a polysaccharide from Grifola frondosa on tumor growth involve activation of NK cells". Biological & Pharmaceutical Bulletin. 25 (12): 1647–50.
Kodama N, Asakawa A, Inui A, Masuda Y, Nanba H (2005). "Enhancement of cytotoxicity of NK cells by D-Fraction, a polysaccharide from Grifola frondosa". Oncology Reports. 13 (3): 497–502.
Kodama N, Komuta K, Nanba H (2002). "Can maitake MD-fraction aid cancer patients?". Alternative Medicine Review. 7 (3): 236–9.
Nanba H, Kubo K (1997). "Effect of Maitake D-fraction on cancer prevention". Annals of the New York Academy of Sciences. 833 (1 Cancer): 204–7.
Masuda Y, Murata Y, Hayashi M, Nanba H (2008). "Inhibitory effect of MD-Fraction on tumor metastasis: involvement of NK cell activation and suppression of intercellular adhesion molecule (ICAM)-1 expression in lung vascular endothelial cells". Biological & Pharmaceutical Bulletin. 31 (6): 1104–8.
Konno S, Tortorelis DG, Fullerton SA, Samadi AA, Hettiarachchi J, Tazaki H (2001). "A possible hypoglycaemic effect of maitake mushroom on Type 2 diabetic patients". Diabetic Medicine. 18 (12): 1010.
Hong L, Xun M, Wutong W (2007). "Anti-diabetic effect of an alpha-glucan from fruit body of maitake (Grifola frondosa) on KK-Ay mice". The Journal of Pharmacy and Pharmacology. 59 (4): 575–82.
Kubo K, Aoki H, Nanba H (1994). "Anti-diabetic activity present in the fruit body of Grifola frondosa (Maitake). I". Biological & Pharmaceutical Bulletin. 17 (8): 1106–10.
Lo HC, Hsu TH, Chen CY (2008). "Submerged culture mycelium and broth of Grifola frondosa improve glycemic responses in diabetic rats". The American Journal of Chinese Medicine. 36 (2): 265–85.
Manohar V, Talpur NA, Echard BW, Lieberman S, Preuss HG (2002). "Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice". Diabetes, Obesity & Metabolism. 4 (1): 43–8.
Horio H, Ohtsuru M (2001). "Maitake (Grifola frondosa) improve glucose tolerance of experimental diabetic rats". Journal of Nutritional Science and Vitaminology. 47 (1): 57–63.
Matsuur H, Asakawa C, Kurimoto M, Mizutani J (2002). "Alpha-glucosidase inhibitor from the seeds of balsam pear (Momordica charantia) and the fruit bodies of Grifola frondosa". Bioscience, Biotechnology, and Biochemistry. 66 (7): 1576–8.
Zhang Y, Mills GL, Nair MG (2002). "Cyclooxygenase inhibitory and antioxidant compounds from the mycelia of the edible mushroom Grifola frondosa". Journal of Agricultural and Food Chemistry. 50 (26): 7581–5.
Lee JS, Park BC, Ko YJ, et al. (2008). "Grifola frondosa (maitake mushroom) water extract inhibits vascular endothelial growth factor-induced angiogenesis through inhibition of reactive oxygen species and extracellular signal-regulated kinase phosphorylation". Journal of Medicinal Food. 11 (4): 643–51.
Lin H, She YH, Cassileth BR, Sirotnak F, Cunningham Rundles S. (2004) "Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro".
Wasser, SP; Weis AL (1999). "Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective". Critical reviews in immunology. (United States: Begell House) 19 (1): 65–96.
Miura, NN; Ohno N, Aketagawa J, Tamura H, Tanaka S, Yadomae T (1996). "Blood clearance of (1-->3)-beta-D-glucan in MRL lpr/lpr mice". FEMS immunology and medical microbiology. (England: Blackwell Publishing) 13 (1): 51–57.
Brown, GD; Gordon, S (2001). "Immune recognition. A new receptor for beta-glucans.". Nature. 413 (6851): 36–7.
Vetvicka, V; Dvorak B, Vetvickova J, Richter J, Krizan J, Sima P, Yvin JC (2007). "Orally administered marine (1-->3)-beta-D-glucan Phycarine stimulates both humoral and cellular immunity". International journal of biological macromolecules. (England: Butterworth-Heinemann) 40 (4): 291–298.
Boeki Center Building
5-1-14 Hamabetori Chuo-ku
TEL: +81 (0)6-6902-5251
FAX: +81 (0)6-6902-7133
Nature 21 Building
TEL: +81 (0)6-6902-1001
ORE Hiroo Building
ORE Hiroo Building
Nature 21 Building